Refine
Year of publication
Document Type
- Preprint (574)
- Article (390)
- Working Paper (2)
Has Fulltext
- yes (966)
Is part of the Bibliography
- no (966)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (5)
- Jets (5)
- Atmospheric chemistry (4)
- Collective Flow (4)
- Heavy Quark Production (4)
- Quark-Gluon Plasma (4)
- Burden of illness (3)
- Healthcare costs (3)
- Jets and Jet Substructure (3)
- Prevalence (3)
- Artificial intelligence (2)
- Atmospheric science (2)
- Climate change (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Healthcare resource utilization (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Machine learning (2)
- Oncology (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- QCD (2)
- Quark Gluon Plasma (2)
- Quarkonium (2)
- Radiomics (2)
- Rescue medication (2)
- Shell model (2)
- brain metastases (2)
- breast cancer (2)
- ALICE detector (1)
- ATR-FTIR (1)
- Analysis and statistical methods (1)
- Anti-nuclei (1)
- Antidepressant (1)
- B cell receptor (1)
- BCL2 (1)
- BCR-ABL (1)
- BPH (1)
- BPO (1)
- Biogeochemistry (1)
- Biomarker (1)
- Bipolar disorder (1)
- Boosted Jets (1)
- Breast cancer (1)
- CLOUD experiment (1)
- COVID-19 (1)
- CTLA-4 (1)
- CaMPARI (1)
- Calorimeters (1)
- Cancer detection and diagnosis (1)
- Circadian (1)
- Climate-change impacts (1)
- Coagulation (1)
- Collective Flow, (1)
- Cost-effectiveness (1)
- Critical care (1)
- Data processing methods (1)
- Depression (1)
- Direct reactions (1)
- Dravet syndrome (1)
- Drug screens (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Epilepsy (1)
- Fibre/foam sandwich radiator (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- HNSCC (1)
- HOLEP (1)
- HPV-positive OPSCC (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Health technology assessment (1)
- Healthcare resource utilisation (1)
- Heavy Ion Experiment (1)
- Heavy Ions (1)
- Heavy-Ion Collision (1)
- Heavy-ion detectors (1)
- Hematology (1)
- High-energy neutron detection (1)
- Histology (1)
- Human genetics (1)
- IPSS (1)
- Inflammation (1)
- Intensive care (1)
- Inverse kinematics (1)
- Ion channels in the nervous system (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- KIF (1)
- KIF11 (1)
- LHC (1)
- Large detector systems for particle and astroparticle physics (1)
- Lee type, functional outcome (1)
- Lee-type (1)
- Lennox-Gastaut syndrome (1)
- Leukemias (1)
- Loco-regional control (1)
- Material budget (1)
- Mechanical ventilation (1)
- Molecular neuroscience (1)
- Mortality (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-wire proportional drift chamber (1)
- Multiparametric MRI (1)
- Multiphoton microscopy (1)
- Myocardial injury (1)
- NCH93 (1)
- Neural network (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORP (1)
- Optogenetics (1)
- Ovarian cancer (1)
- PAD-test (1)
- PD-1 (1)
- PSA (1)
- Particle and Resonance Production (1)
- Pb–Pb collisions (1)
- Performance of High Energy Physics Detectors (1)
- Plastic scintillator array (1)
- Prediction (1)
- Primary care (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Psychiatry (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quasi-free scattering (1)
- RARP (1)
- Reactions with relativistic radioactive beams (1)
- Relativistic heavy-ion collisions (1)
- Seasonal variation (1)
- Solar insolation (1)
- Spectroscopic factors (1)
- Spectroscopic factors & electromagnetic moments (1)
- Suicide (1)
- Sunlight (1)
- TR (1)
- Thermodynamics (1)
- Tracking (1)
- Transition radiation detector (1)
- Treatment (1)
- Trigger (1)
- Tuberous sclerosis complex (1)
- Validation (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- activation receptors (1)
- acute lymphoblastic leukaemia (1)
- aerosol formation (1)
- aerosols (1)
- allogeneic stem cell transplant (1)
- antibiotic resistance (1)
- apex (1)
- articular chondrocytes (1)
- asymptomatic (1)
- bloodstream infections (1)
- bone metabolism (1)
- bone morphogenetic proteins (BMPs) (1)
- chemical biology (1)
- chemotherapy (1)
- combined modality therapy (1)
- congenic mice (1)
- cytosolic free calcium (1)
- dE/dx (1)
- detector (1)
- deubiquitylating enzymes (1)
- double immune checkpoint inhibition (1)
- ectosomes (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- functional outcome (1)
- fusion biopsy (1)
- gravity (1)
- guidelines (1)
- head and neck neoplasms (1)
- heavy ion experiments (1)
- hepatic osteodystrophy (1)
- high throughput screening (1)
- histone deacetylases (HDACs) (1)
- image-based risk modelling (1)
- immune checkpoint blockade (1)
- immunotherapy (1)
- induction therapy (1)
- inflammation (1)
- innate lymphoid cells (1)
- intensive care admission and mortality (1)
- intracellular trafficking (1)
- isoforms (1)
- kinesin (1)
- liver disease (1)
- liver metastasis (1)
- machine learning (1)
- mass spectrometry (1)
- membranous urethra (1)
- meningioma (1)
- metabolic syndrome (1)
- miRNA-17–92 (1)
- microparticles (1)
- microvesicles (1)
- mid-term urinary continence (1)
- minimal information requirements (1)
- nanoparticle growth (1)
- obesity (1)
- organ preservation (1)
- osteopenia (1)
- osteoporosis (1)
- packaging (1)
- parabolic flight (1)
- pediatric patients (1)
- personalised therapy (1)
- photochemistry (1)
- photopolymerization (1)
- prognostic scores (1)
- prostate cancer (1)
- proteomics (1)
- psoriasis (1)
- quark gluon plasma (1)
- radiation oncology (1)
- radical prostatectomy (1)
- radiomic (1)
- reproducibility (1)
- rigor (1)
- sclerostin (1)
- secukinumab (1)
- standardization (1)
- systematic biopsy (1)
- transforming growth factor beta (TGF-β) (1)
- treatment resistance (1)
- ubiquitin specific proteases (1)
- uveal melanoma (1)
- vitamin Dmetabolism (1)
- volatile organic compounds (1)
Institute
- Physik (882)
- Frankfurt Institute for Advanced Studies (FIAS) (812)
- Informatik (779)
- Geowissenschaften (33)
- Medizin (33)
- ELEMENTS (6)
- Geowissenschaften / Geographie (5)
- Informatik und Mathematik (4)
- Biowissenschaften (2)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (2)
Kinesins play an important role in many physiological functions including intracellular vesicle transport and mitosis. The emerging role of kinesins in different cancers led us to investigate the expression and functional role of kinesins in meningioma. Therefore, we re-analyzed our previous microarray dataset of benign, atypical, and anaplastic meningiomas (n = 62) and got evidence for differential expression of five kinesins (KIFC1, KIF4A, KIF11, KIF14 and KIF20A). Further validation in an extended study sample (n = 208) revealed a significant upregulation of these genes in WHO°I to °III meningiomas (WHO°I n = 61, WHO°II n = 88, and WHO°III n = 59), which was most pronounced in clinically more aggressive tumors of the same WHO grade. Immunohistochemical staining confirmed a WHO grade-associated upregulated protein expression in meningioma tissues. Furthermore, high mRNA expression levels of KIFC1, KIF11, KIF14 and KIF20A were associated with shorter progression-free survival. On a functional level, knockdown of kinesins in Ben-Men-1 cells and in the newly established anaplastic meningioma cell line NCH93 resulted in a significantly inhibited tumor cell proliferation upon siRNA-mediated downregulation of KIF11 in both cell lines by up to 95% and 71%, respectively. Taken together, in this study we were able to identify the prognostic and functional role of several kinesin family members of which KIF11 exhibits the most promising properties as a novel prognostic marker and therapeutic target, which may offer new treatment options for aggressive meningiomas.
The evolution of the traditional nuclear magic numbers away from the valley of stability is an active field of research. Experimental efforts focus on providing key spectroscopic information that will shed light into the structure of exotic nuclei and understanding the driving mechanism behind the shell evolution. In this work, we investigate the spin-orbit shell gap towards the neutron dripline. To do so, we employed (p,2p) quasi-free scattering reactions to measure the proton component of the state of 16,18,20C. The experimental findings support the notion of a moderate reduction of the proton spin-orbit splitting, at variance to recent claims for a prevalent magic number towards the neutron dripline.
The balance function is a new observable based on the principle that charge is locally conserved when particles are pair produced. Balance functions have been measured for charged particle pairs and identified charged pion pairs in Au+Au collisions at sqrt[sNN]=130 GeV at the Relativistic Heavy Ion Collider using STAR. Balance functions for peripheral collisions have widths consistent with model predictions based on a superposition of nucleon-nucleon scattering. Widths in central collisions are smaller, consistent with trends predicted by models incorporating late hadronization.
Azimuthal anisotropy (v2) and two-particle angular correlations of high pT charged hadrons have been measured in Au+Au collisions at sqrt[sNN]=130 GeV for transverse momenta up to 6 GeV/c, where hard processes are expected to contribute significantly. The two-particle angular correlations exhibit elliptic flow and a structure suggestive of fragmentation of high pT partons. The monotonic rise of v2(pT) for pT<2 GeV/c is consistent with collective hydrodynamical flow calculations. At pT>3 GeV/c, a saturation of v2 is observed which persists up to pT=6 GeV/c.
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance (AR). A multinational, multicenter retrospective study in patients aged ≤ 18 years, treated with chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need of ICU admission were significantly associated with mortality. Center-level variation showed a greater impact on AR, while patient-level variation had more effect on ICU admission and mortality. Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI. Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a significant role for the treating center too. The significant evidence of center-level variations on AR, ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection control programs.
Objective: To investigate the value of standard [digital rectal examination (DRE), PSA] and advanced (mpMRI, prostate biopsy) clinical evaluation for prostate cancer (PCa) detection in contemporary patients with clinical bladder outlet obstruction (BOO) scheduled for Holmium laser enucleation of the prostate (HoLEP).
Material and Methods: We retrospectively analyzed 397 patients, who were referred to our tertiary care laser center for HoLEP due to BOO between 11/2017 and 07/2020. Of those, 83 (20.7%) underwent further advanced clinical PCa evaluation with mpMRI and/or prostate biopsy due to elevated PSA and/or lowered PSA ratio and/or suspicious DRE. Logistic regression and binary regression tree models were applied to identify PCa in BOO patients.
Results: An mpMRI was conducted in 56 (66%) of 83 patients and revealed PIRADS 4/5 lesions in 14 (25%) patients. Subsequently, a combined systematic randomized and MRI-fusion biopsy was performed in 19 (23%) patients and revealed in PCa detection in four patients (5%). A randomized prostate biopsy was performed in 31 (37%) patients and revealed in PCa detection in three patients (4%). All seven patients (9%) with PCa detection underwent radical prostatectomy with 29% exhibiting non-organ confined disease. Incidental PCa after HoLEP (n = 76) was found in nine patients (12%) with advanced clinical PCa evaluation preoperatively. In univariable logistic regression analyses, PSA, fPSA ratio, and PSA density failed to identify patients with PCa detection. Conversely, patients with a lower International Prostate Symptom Score (IPSS) and PIRADs 4/5 lesion in mpMRI were at higher risk for PCa detection. In multivariable adjusted analyses, PIRADS 4/5 lesions were confirmed as an independent risk factor (OR 9.91, p = 0.04), while IPSS did not reach significance (p = 0.052).
Conclusion: In advanced clinical PCa evaluation mpMRI should be considered in patients with elevated total PSA or low fPSA ratio scheduled for BOO treatment with HoLEP. Patients with low IPSS or PIRADS 4/5 lesions in mpMRI are at highest risk for PCa detection. In patients with a history of two or more sets of negative prostate biopsies, advanced clinical PCa evaluation might be omitted.
Safety requirements and the need of low‐migration UV inks have received increasing attention in the packaging industry. Crucial for the development and design of low‐migration UV inkjet inks for migration‐sensitive applications is the polymerization degree. In this study, curing‐behavior of a black, high purity packaging ink (HPP‐ink) was monitored using ATR‐FTIR spectroscopy. UV irradiation of HPP‐ink led to changes in specific absorption bands of the FTIR spectra due to crosslinking reaction of double bonds. Changes in absorptions bands at 1,408 and 1,321 cm−1 permitted the determination of CC conversion of acrylic and vinyl double bond, independently of one another. In addition, a method was developed which allows the investigation of surface‐cure and deep‐cure behavior, separately.
Simple Summary: The incidence of brain metastases from breast cancer is increasing and the treatment is still a major challenge. Several scores have been developed in order to estimate the prognosis of patients with brain metastases by objective criteria. Here, we validated all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer patients with brain metastases in the Brain Metastases in the German Breast Cancer (BMBC) registry. Although all three available GPA-scores were associated with OS, they all show limitations mainly in predicting short-term (below 3 months) survival but also in long-term (above 12 months) survival. We discuss the test performances of all scores in our work and provide evidence how physicians should use them as a tool to select patients for different treatment options.
Abstract: Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis (p < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.
Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases
(2020)
Simple Summary: The prognosis for patients with breast cancer that has spread to the brain is poor, and survival for these women hasn’t improved over the last few decades. We do not currently test for asymptomatic brain metastases in breast cancer patients, although this does happen in some other types of cancer. In this study we wanted to find out more about breast cancer that has spread to the brain and in particular to see whether there might be any advantage to spotting brain metastases before the development of neurological symptoms. Overall, our results suggest that women could be better off if their brain metastases are diagnosed before they begin to cause symptoms. We now need to carry out a clinical trial to see what happens if we screen high-risk breast cancer patients for brain metastases. This will verify whether doing so could increase survival, symptom control or quality of life.
Abstract: Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80–100%: 68.4% vs. 57%, p < 0.001), a lower number of BM (>1 BM: 56% vs. 70%, p = 0.027), and a slightly smaller diameter of BM (median: 1.5 vs. 2.2 cm, p < 0.001). Asymptomatic patients were more likely to have extracranial metastases (86.7% vs. 81.5%, p = 0.003) but were less likely to have leptomeningeal metastasis (6.3% vs. 10.9%, p < 0.001). Asymptomatic patients underwent less intensive BM therapy but had a longer median overall survival (statistically significant for a cohort of HER2-positive patients) compared to symptomatic patients (10.4 vs. 6.9 months, p < 0.001). Conclusions: These analyses show a trend that asymptomatic patients have less severe metastatic brain disease and despite less intensive local BM therapy still have a better outcome (statistically significant for a cohort of HER2-positive patients) than patients who present with symptomatic BM, although a lead time bias of the earlier diagnosis cannot be ruled out. Our analysis is of clinical relevance in the context of potential trials examining the benefit of early detection and treatment of BM.